Nemucore Medical Innovations Revenue and Competitors
Estimated Revenue & Valuation
- Nemucore Medical Innovations's estimated annual revenue is currently $775k per year.
- Nemucore Medical Innovations's estimated revenue per employee is $155,000
Employee Data
- Nemucore Medical Innovations has 5 Employees.
- Nemucore Medical Innovations grew their employee count by 0% last year.
Nemucore Medical Innovations's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP Operations | Reveal Email/Phone |
Nemucore Medical Innovations Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Nemucore Medical Innovations?
We envision a world where patients with cancer receive an effective drug the first time. About 30% of patients have mutations in their DNA that indicate they'll respond well to certain drugs; we develop drugs for the other 70%. We combined our drug, NMI-900, with a unique diagnostic that measures RNA rather than DNA. Our approach has the potential to select the right patient, improve survival, and limit side effects. In 5 years, we look forward to regulatory approval in AML and helping patients. Find out more at: https://wefunder.com/nemucore.medical.innovations.inc
keywords:N/AN/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A |
#2 | $0.4M | 6 | 0% | N/A |
#3 | $0.5M | 7 | N/A | N/A |
#4 | $0.5M | 7 | -12% | N/A |
#5 | $0.7M | 9 | 13% | N/A |